Starting January 2026, you may have an alternative to the injection: CV Risk Reduction: Alternative Coverage Pathway Wegovy is the only obesity medication FDA-approved to reduce cardiovascular risk (March 2024)
[5] Several biological mechanisms have been proposed in preclinical research that suggest plausible links between GLP-1 signalling and brain health: Neuroprotection : In laboratory and animal studies, GLP-1 receptor activation may protect neurons from oxidative stress and inflammation, both of which contribute to neurodegeneration [5] Neurogenesis : Animal studies suggest GLP-1 may promote the growth of new neurons in the hippocampus, a region essential for memory Reduction of amyloid plaques : Preclinical research indicates potential effects on beta-amyloid accumulation, a hallmark of Alzheimer's disease [5] Anti-inflammatory effects : Chronic neuroinflammation is implicated in various forms of dementia The connection between metabolic health and cognitive function provides additional rationale for investigating GLP-1 agents in dementia
LW RX Wins Ro Dropped Compounded Semaglutide: After the FDA resolved the semaglutide shortage in February 2025, Ro pivoted to brand-name only medications (Wegovy/Zepbound), dramatically increasing patient costs
Place the medication in the passenger cabin, not the trunk
The endothelial glycocalyx and its disruption, protection and regeneration: a narrative review
We recommend patients reduce their portion size and stop eating once they start feeling full when starting the medication
